Promise Bio Ltd. emerged from stealth with $8.3 million in seed investment for its precision medicine platform, which addresses immune-mediated diseases. The funding will be used to accelerate the development of the company’s technology that analyzes proteins and their post-translational modifications to predict the treatment responses of patients with immune-mediated diseases.
Alexander Shulgin Research Institute has described phenylalkylamine compounds reported to be useful for the treatment of pain, inflammation, neurodegeneration, stroke, ischemia-reperfusion injury and psychiatric disorders.
University of Washington has divulged compounds acting as methionyl-tRNA synthetase (bacterial) inhibitors reported to be useful for the treatment of bacterial and protozoal infections.
Researchers at Chengdu Brilliant Pharmaceutical Co. Ltd. and Scinnohub Pharmaceutical Co. Ltd. have disclosed 15-hydroxyprostaglandin dehydrogenase inhibitors reported to be useful for the treatment of diabetes, osteoporosis and more.
Researchers from Engrail Therapeutics Inc. recently described the pharmacological characterization of ENX-105, a new class of molecule that combines 5-HT1A/2A receptor agonism with D2/3 receptor antagonism, to be used for its antianhedonic and antipsychotic effects.
Scientists from the Miller School of Medicine at the University of Miami have reported their recent work to develop small-molecule inhibitors of the CD40-CD40L (CD154) costimulatory protein-protein interaction.
Cancer immunotherapies are highly effective treatments for treating hematological malignancies, but usually tied to systemic toxicity, including cytokine release syndrome (CRS).
Inceptor Bio LLC and Shenzhen Grit Biotechnology Co. Ltd. have established a strategic partnership to advance IB-T101, a CAR T therapy targeting solid tumors.
RSS
